Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF inactivation drives aneuploidy by deregulating CRAF.

Cancer research - 1 Nov 2010

Kamata Tamihiro, Hussain Jahan, Giblett Susan, Hayward Robert, Marais Richard, Pritchard Catrin

Abstract excerpt

Aspartate-594 is the third most common BRAF residue mutated in human cancer. Mutants of this residue are kinase inactive, and the mechanism(s) by which they contribute to cancer has remained perplexing. Using a conditional knock-in mouse model, we show that the (D594A)Braf mutant does not drive tumor development per se but is able to induce aneuploidy in murine splenocytes and mouse embryonic fibroblasts and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aneuploidy
Share to Cellular Senescence
Share to Chromosomal Instability

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mitogen-Activated Protein Kinases

Share to Monocytes

Share to Spleen

Source

Open in PubMed Open full text

Identifiers

PMID: 20978199
DOI: 10.1158/0008-5472.CAN-10-0603
PMCID: PMC2975377

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF inactivation drives aneuploidy by deregulating CRAF.PMID 20978199Read ↗

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.Semantic proximity Read ↗

The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.Semantic proximity Read ↗

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.Semantic proximity Read ↗

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.Semantic proximity Read ↗

CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation.Semantic proximity Read ↗

CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibitionSemantic proximity Read ↗

Differential contribution for ERK1 and ERK2 kinases in BRAFV600E-triggered phenotypes in adult mouse models.Semantic proximity Read ↗

Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts.Semantic proximity Read ↗

Oncogenic B-Raf(V600E) induces spindle abnormalities, supernumerary centrosomes, and aneuploidy in human melanocytic cells.Semantic proximity Read ↗

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.Semantic proximity Read ↗

Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis.Semantic proximity Read ↗

Endothelial apoptosis in Braf-deficient mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.